Navigation Links
Breast Cancer Gene Might Extend Ovarian Cancer Survival
Date:1/3/2008

The finding is so far limited to women of Ashkenazi Jewish descent, researchers say

THURSDAY, Jan. 3 (HealthDay News) -- Ashkenazi Jewish women with ovarian cancer live significantly longer if they carry specific mutations of the BRCA1 or BRCA2 genes known to raise risks for breast cancer.

After five years of following a group of Ashkenazi Jewish women with ovarian cancer, researchers reported that women with the BRCA1 or 2 mutations were 29 percent less likely to die from the disease.

The Israel-based research team compared five-year survival between 213 Ashkenazi ovarian cancer patients with BRCA1 or 2 mutations ("carriers") and 392 Ashkenazi ovarian cancer patients without the mutations ("non-carriers").

After five years of follow-up, almost half (46 percent) of the carriers had survived, compared with about a third (34.4 percent) of non-carriers. Median survival was almost 54 months for women carrying a mutation and just under 38 months for non-carriers. Survival differed most strongly for women diagnosed with more advanced disease (stage III or IV) -- carriers had five-year survival rates of 38.1 percent versus 24.5 percent for non-carriers. Other factors, such as age and tumor size, did not alter the effect of the genetic mutation.

The researchers also looked at ovarian cancer survival depending on whether women had a BRCA1 or a BRCA2 mutation. Women with BRCA1 mutations lived a median of just over 45 months, and women with BRCA2 mutations lived a median of 52.5 months, the study found.

"These findings are encouraging news for BRCA mutation carriers," Dr. Siegal Sadetzki, head of the Cancer & Radiation Epidemiology Unit at the Gertner Institute, Chaim Sheba Medical Center in Tel Hashomer, Israel, said in a prepared statement. "It's possible that patients with these mutations respond better to chemotherapy -- hopefully, once we learn more about the mechanisms of this response, tailoring individual treatment will further improve survival."

Normal BRCA1/2 genes control cell growth. Mutations in these genes, which are more common among Ashkenazi Jewish women than in the general population, increase the risk of breast and ovarian cancers. Ashkenazi Jews are of Eastern European descent.

The study is published in the January issue of the Journal of Clinical Oncology.

More information

To learn more about ovarian cancer, visit the U.S. Centers for Disease Control and Prevention.



-- Madeline Vann



SOURCE: American Society of Clinical Oncology, news release, Jan. 1, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Survival differences by race most apparent in advanced stages of breast cancer
2. MRI finds breast cancer before it becomes dangerous
3. Pathway links inflammation, angiogenesis and breast cancer
4. Drop in breast cancer incidence linked to hormone use, not mammograms
5. Breast cancer prevention practices vary across Canada
6. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
7. Acrylamide Wont Raise Breast Cancer Risk
8. New link between estrogen and breast cancer
9. Hypnosis Eases Pain of Breast Cancer Surgery
10. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
11. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... ... ... A recent article published June 14 on E Online details ... to state that individuals are now more comfortable seeking to undergo not only the ... and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) notes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... One of Australia,s successful biotechnology ... a new biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ... to list on the ASX. Noxopharm is a clinic-ready ... a Phase 1 clinical study later this year. ... the biggest problems facing cancer patients - the ability of cancers ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... Antitrust Improvements Act of 1976, as amended ("HSR"), with ... ("Celator"; Nasdaq: CPXX ) expired effective June ... As previously announced on May 31, 2016, Jazz ... under which Jazz Pharmaceuticals has commenced a tender offer ...
(Date:6/26/2016)... OTTAWA, Ontario , June 27, 2016  VMS ... the Company,s Board will take whatever measures required to ... the Company,s stock which is currently listed on the ... S Wexler, Company Chairman and CEO, "We are seeing ... be difficult to understand, not only by the Company, ...
Breaking Medicine Technology: